Antihypertensive Animals Models Using Epinephrine Induction
Keywords:
antihypertensive, animal models, epinephrine, invasive method, tail cuff methodAbstract
Hypertension is characterized by elevated blood pressure levels above the norm. Animal research is one method for discovering novel antihypertensive medicines. The primary goal of this study is to create a rapid method for assessing the antihypertensive effects of various medications, including propranolol, atenolol, amlodipine, captopril, and losartan, on epinephrine-induced hypertension. To achieve this, the researchers used a hypertension model involving the administration of epinephrine to test animals. The animals were divided into seven groups: a normal control group and six treatment groups, each receiving a different antihypertensive medication. The medications were administered at specific doses, and the animals' blood pressure was measured every 15 minutes for 60 minutes using the Kent Scientific CODA system. The results were analyzed statistically to determine the differences in systolic and diastolic blood pressure between the groups. The results indicated that epinephrine increased systolic and diastolic blood pressure in comparison to the normal group (p<0.05), with the greatest increase occurring 30 minutes after induction. The suitable antihypertensive for this method is propranolol and amlodipine with onset of reaction is the fastest. These findings indicate that epinephrine induction can be used to screen for antihypertensive effects and is classified as simple and quick.
References
Abraham, H. M. A., White, C. M., & White, W. B. (2015). The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Safety, 38(1), 33–54. https://doi.org/10.1007/s40264-014-0239-7
Al-Majed, A. A., Bakheit, A. H. H., Abdel Aziz, H. A., Alajmi, F. M., & AlRabiah, H. (2017). Propranolol. In Profiles of Drug Substances, Excipients and Related Methodology (Vol. 42, pp. 287–338). Elsevier. https://doi.org/10.1016/bs.podrm.2017.02.006
Al-Majed, A.-R. A., Assiri, E., Khalil, N. Y., & Abdel-Aziz, H. A. (2015). Losartan. In Profiles of Drug Substances, Excipients and Related Methodology (Vol. 40, pp. 159–194). Elsevier. https://doi.org/10.1016/bs.podrm.2015.02.003
Arora, P. K., & Chauhan, A. (2013). ACE inhibitors: a comprehensive review. International Journal of Pharmaceutical Sciences and Research, 4(2), 523–549.
BPOM. (2023). Peraturan Badan Pengawas Obat dan Makanan No. 23 Tahun 2023 tentang Pendoman Uji Farmakodinamik Praklinik Obat Tradisional. Badan Pengawas Obat dan Makanan Republik Indonesia.
Bulsara, K., Patel, P., & Cassagnol, M. (2025). Amlodipine. StatPearls Publishing. https://https://www.ncbi.nlm.nih.gov/books/NBK519508/
Fares, H., DiNicolantonio, J. J., O’Keefe, J. H., & Lavie, C. J. (2016). Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart, 3(2), e000473. https://doi.org/10.1136/openhrt-2016-000473
Floras, J. S. (1992). Epinephrine and the genesis of hypertension. Hypertension, 19(1), 1–18. https://doi.org/10.1161/01.HYP.19.1.1
Kumar, A., Joshi, A., & Starling, S. K. (2011). β-Blockers: A systematic review. Journal of Chemical and Pharmaceutical Research, 3(1), 32–47.
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., Azizi, M., Benetos, A., Borghi, C., Hitij, J. B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J. K., Cunha, P. G., … Kjeldsen, S. E. (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension, 41(12), 1874–2071. https://doi.org/10.1097/HJH.0000000000003480
Morales-Cané, I., Valverde-León, M. D. R., & Rodríguez-Borrego, M. A. (2016). Epinephrine in cardiac arrest: Systematic review and meta-analysis. Revista Latino-Americana de Enfermagem, 24(0). https://doi.org/10.1590/1518-8345.1317.2821
Rehman, B., Sanchez, D., Patel, P., & Shah, S. (2025). Atonolol. In StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK539844/
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., Bonny, A., Brauer, M., Brodmann, M., Cahill, T. J., Carapetis, J., Catapano, A. L., Chugh, S. S., Cooper, L. T., Coresh, J., … Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010
Suryani, Sukandar, E. Y., Insanu, M., & Kurniati, N. F. (2020). Evaluation Effect Of Polarity Of The Compound From Sonchus arvensis (Linn.) Leaves As Hypertension Inhibitor. Rasayan Journal of Chemistry, 13(03), 1807–1816. https://doi.org/10.31788/RJC.2020.1335843
Tocci, G., Battistoni, A., Passerini, J., Musumeci, M. B., Francia, P., Ferrucci, A., & Volpe, M. (2015). Calcium Channel Blockers and Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 20(2), 121–130. https://doi.org/10.1177/1074248414555403
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75(6), 1334–1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
World Health Organization. (2023). Hypertension Indonesia 2023 country profile. www.who.int/publications/m/item/hypertension-idn-2023-country-profile
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Afifah Bambang Sutjiatmo, Falna Bintussolihah, Suci Nar Vikasari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercial purposes.
- Adaptation — mixing, changing, and developing materials for any purpose, even commercial ones.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
